Jazz rolls the dice on a bil­lion-dol­lar gam­ble on a new drug for SCLC — shoot­ing for a 2020 launch

Two days af­ter fil­ing their can­cer drug lur­binecte­din in the hunt for an FDA ap­proval, Spain’s Phar­ma­Mar has snagged $200 mil­lion in cash as a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.